HIV藥物市場規模、佔有率、成長分析（按藥物類別、藥物類型、分銷管道和地區）－2025-2032年產業預測

HIV Drugs Market Size, Share, and Growth Analysis, By Medication Class (Multi-class Combination Drugs, Nucleoside-Analog Reverse Transcriptase Inhibitors ), By Drug Type, By Distribution Channel, By Region - Industry Forecast 2025-2032

出版日期: 2025年04月02日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計 2023 年全球愛滋病治療藥物市場價值將達到 345.7 億美元，從 2024 年的 360.9 億美元成長到 2032 年的 509.3 億美元，預測期內（2025-2032 年）的複合年成長率為 4.4%。

由於全球愛滋病毒感染者人數不斷增加，預計愛滋病毒藥物市場將出現強勁成長。人們對愛滋病毒認知的提高以及對先進治療方案的需求不斷成長預計將在未來幾年進一步促進銷售。抗逆轉錄病毒療法 (ART) 的創新，受到對增強型愛滋病毒藥物開發的大量投資的推動，將對市場產生重大影響。政府致力於提高人們對愛滋病毒的認知和預防，預計將在長期內支持藥品銷售，而對早期檢測和診斷的重視將為製藥公司創造新的機會。然而，抗藥性、副作用、社會恥辱以及某些治療方法的高成本等挑戰可能會阻礙 2031 年以後的整體市場需求。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業市場定位（2024年）
主要市場參與者所採取的策略
近期市場趨勢
公司市場佔有率分析（2024年）
主要企業簡介
- 公司詳情
- 產品系列分析
- 公司分部佔有率分析
- 收益與前一年同期比較對比（2022-2024 年）
  主要企業簡介
  - 吉利德科學公司（美國）
  - ViiV Healthcare（英國）
  - 默克公司（美國）
  - 百時美施貴寶公司（美國）
  - 艾伯維公司（美國）
  - 勃林格殷格翰國際有限公司（德國）
  - F. Hoffmann-La Roche AG（瑞士）
  - 西普拉公司（印度）
  - 梯瓦製藥工業股份有限公司（以色列）
  - 異性戀藥物（印度）
  - 巴塞利亞製藥公司（瑞士）
  - Advanz Pharma（英國）
  - 太陽製藥工業有限公司（印度）
  - 奧羅賓多製藥（印度）
  - 雷迪博士實驗室（印度）
  - 魯賓有限公司（印度）
  - 麥克勞茲製藥有限公司（印度）
  - Glenmark 製藥公司（印度）
  - Torrent Pharmaceuticals Ltd.（印度）
  - Zydus Lifesciences Limited（印度）

結論和建議

簡介目錄

Product Code: SQMIG35I2310

Global HIV Drugs Market size was valued at USD 34.57 billion in 2023 and is poised to grow from USD 36.09 billion in 2024 to USD 50.93 billion by 2032, growing at a CAGR of 4.4% during the forecast period (2025-2032).

The rising global prevalence of HIV infections is set to drive strong growth in the HIV drugs market. Increased awareness of HIV, alongside growing demand for advanced treatment options, is expected to further elevate sales in the coming years. Innovations in antiretroviral therapy (ART) will significantly influence the market, supported by substantial investment in the development of enhanced HIV therapeutics. Government initiatives focused on HIV awareness and prevention are anticipated to support long-term drug sales, while an emphasis on early testing and diagnostics opens new business opportunities for pharmaceutical companies. However, challenges such as drug resistance, side effects, social stigma, and the high cost of certain treatments may hinder overall demand in the market landscape through 2031 and beyond.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Hiv Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Hiv Drugs Market Segments Analysis

Global HIV Drugs Market is segmented by Medication Class, Drug Type, Distribution Channel and region. Based on Medication Class, the market is segmented into Multi-class Combination Drugs, Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs), Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Entry & Fusion Inhibitors, Protease Inhibitors (PIs), Integrase Inhibitors and Coreceptor Antagonists. Based on Drug Type, the market is segmented into Branded Drugs and Generic Drugs. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Hiv Drugs Market

The global HIV drugs market is being propelled by the proactive initiatives launched by governments and public health organizations aimed at enhancing awareness and support for HIV treatment. These programs are designed to increase accessibility to HIV medications for patients worldwide, with a particular focus on aiding individuals in low- to middle-income countries. By improving the reach and availability of these essential drugs, these initiatives are anticipated to significantly benefit affected populations, ultimately contributing to better health outcomes and reduced transmission rates in diverse regions across the globe.

Restraints in the Global Hiv Drugs Market

Drug resistance represents a significant challenge within the global HIV drugs market, posing a serious constraint on its growth prospects. The emergence of drug-resistant HIV strains is primarily driven by inconsistent adherence to prescribed medication regimens. This situation not only narrows treatment options available to patients but also complicates disease management strategies. Furthermore, the necessity for alternative therapies to combat these resistant strains slows down the overall potential for market expansion. As a result, addressing the issue of drug resistance is critical for the sustained development and effectiveness of HIV treatment solutions in the global healthcare landscape.

Market Trends of the Global Hiv Drugs Market

The global HIV drugs market is increasingly leaning towards dual therapy as a strategic trend, with pharmaceutical companies seizing the opportunity to enhance patient outcomes while minimizing side effects associated with traditional antiretroviral treatments. This trend not only addresses the growing demand for reduced toxicity but also alleviates the pill burden that patients face, promoting better adherence to treatment regimens. As regulatory bodies continue to support innovative treatment approaches, dual therapy is positioned to gain traction, allowing companies to expand their business scope and cater to a more health-conscious consumer base, thus reshaping the landscape of HIV management in the coming years.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Regulatory Analysis
Patent Analysis

Global HIV Drugs Market Size by Medication Class & CAGR (2025-2032)

Market Overview
Multi-class Combination Drugs
Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Entry & Fusion Inhibitors
Protease Inhibitors (PIs)
Integrase Inhibitors
Coreceptor Antagonists

Global HIV Drugs Market Size by Drug Type & CAGR (2025-2032)

Market Overview
Branded Drugs
Generic Drugs

Global HIV Drugs Market Size by Distribution Channel & CAGR (2025-2032)

Market Overview
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Global HIV Drugs Market Size & CAGR (2025-2032)

North America (Medication Class, Drug Type, Distribution Channel)
- US
- Canada
Europe (Medication Class, Drug Type, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Medication Class, Drug Type, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Medication Class, Drug Type, Distribution Channel)
- Brazil
- Rest of Latin America
Middle East & Africa (Medication Class, Drug Type, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

Gilead Sciences, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ViiV Healthcare (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim International GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cipla Inc. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hetero Drugs (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Basilea Pharmaceutica (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Advanz Pharma (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sun Pharmaceutical Industries Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aurobindo Pharma (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Dr. Reddy's Laboratories (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lupin Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Macleods Pharmaceuticals Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Glenmark Pharmaceuticals (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Torrent Pharmaceuticals Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Zydus Lifesciences Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments